Drawing for Serial No. 79406989

USPTO serial 79406989

Serial No. 79406989

Reviewed by CopyMark Law Group

Reg. 7910333Status 700Registered
Filing date
Status date
Registration date
Aug 26, 2025
Examiner
PEISECKI, MARK A
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 79406989?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Cheryl L. Burbach

Cheryl L. Burbach Erise IP, P.A.7015 College Blvd.Suite 700Overland Park, KS 66211

Goods and services

ClassDescriptionStatusFirst use
001Biological preparations for use in cell cultures, other than for medical or veterinary purposes, for boosting cells in the immune system for improved therapies; biological preparations for use in cell cultures, in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents in the nature of complexes of molecules for scientific research and for clinical and industrial use; proteins for use in scientific research; regulatory proteins in raw material for scientific researchACTIVE—
005Medical, biological, and pharmaceutical preparations for the treatment of pulmonary diseases; veterinary preparations for pulmonary diseases; medical, biological, and pharmaceutical preparations for preventing and treating infectious diseases, medical disorders, and diseases, namely, lung cancer; veterinary preparations for pets, cattle, livestock for preventing and treating infectious diseases, medical disorders, and diseases, namely, lung cancer; medical, biological, and pharmaceutical preparations for preventing and treating viral, bacterial, and yeast infections; veterinary preparations for pets, cattle, livestock for preventing and treating viral, bacterial, and yeast infections; medical, biological, and pharmaceutical preparations for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; veterinary preparations for pets, cattle, livestock for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, ontological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines; regulatory proteins for medical use, namely, protein arrays for medical diagnosis purposes; pharmaceutical compounds being a component in pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the prevention of diseases of the respiratory system; diagnostic preparations for medical purposes; chemical diagnostic reagents for medical useACTIVE—
040Custom manufacture of pharmaceuticals; custom manufacture of pharmaceuticals, biopharmaceuticals and vaccines in relation to cell therapy, gene editing, protein replacement, and antibodies; provision of information, advice and consultancy services in the field of the aforesaid servicesACTIVE—
042Biological research; clinical research in the field of respiratory diseases, pulmonary diseases, pulmonary surgery; medical research; research and development services in the field of pharmaceutical preparations; pharmaceutical products development; pharmaceutical product evaluation; research in the field of pharmaceuticals; testing of pharmaceuticals; pharmaceutical and medical research and development services in the field of various medical disorders, cancer, pulmonary diseases and infectious diseases; vaccine research and development services; research and development in the field of microorganisms and cells; development of gene-based medicines; drug discovery services; conducting clinical trials for pharmaceutical products for others; scientific laboratory services; laboratory research services relating to pharmaceuticals; Consultancy in the field of pharmaceutical research; Scientific Research services in the nature of conduction clinical trials for others for assessing the efficiency of pharmaceuticals; chemical research and analysis services; medical research and development services in the field of respiratory diseases, pulmonary diseases, cancer; pharmacological research services; scientific research and development in the field of respiratory diseases, pulmonary diseases, cancer; scientific research in the field of respiratory diseases, pulmonary diseases, cancer for medical purposes; scientific research for medical purposes in the area of diseases; conducting clinical trials for others; scientific research in the field of genetics and genetic engineering; genetic research; genetic mapping for scientific purposes; DNA screening for scientific research purposes; DNA analysis services for scientific research purposes; providing scientific information in the field of medical disorders and their treatment; biotechnological research relating to enzymatic synthesis; technical research in the field of pharmaceutical studies; toxicity testing for scientific research purposes; toxicity analysis; information technology services in the nature of on-site management of information technology (IT) systems of others for the pharmaceutical and healthcare industries; Pharmaceutical product evaluation, namely, conducting early evaluations in the field of new pharmaceuticals; providing scientific information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; design and development of computer software relating to the medical field; design and development of computer software relating to healthcare; software as a service (SaaS) featuring artificial intelligence software for healthcare; Software as a service (SaaS) featuring software relating to the medical field; Veterinary research; Provision of information and data relating to medical and veterinary research and developmentACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 23, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 23, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 23, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 23, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 23, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 2, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 2, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 16, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 16, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Mar 14, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 14, 2026FIMPFINAL DISPOSITION PROCESSED—
Nov 26, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 14, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 26, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 26, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 8, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 8, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 2, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 7, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 5, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 5, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 5, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 12, 2025RFNTREFUSAL PROCESSED BY IB—
Mar 28, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 27, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 27, 2025RFRRREFUSAL PROCESSED BY MPU—
Feb 21, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 20, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 13, 2025DOCKASSIGNED TO EXAMINER—
Oct 22, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 22, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 17, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance